Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

• 資料種別: 記事
• タイトル: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
• 著者標目: Kristi McIntyre; Joyce O’Shaughnessy; Lee Schwartzberg; Stefan Glück; Erhan Berrak; James X. Song; David Cox; Linda T. Vahdat
• 出版年月日等: 2014-04-04
• 出版年（W3CDTF）: 2014-04-04
• タイトル（掲載誌）: Breast Cancer Research and Treatment
• 巻号年月日等（掲載誌）: 146 2
• 掲載巻: 146
• 掲載号: 2
• 掲載ページ: 321-328
• 掲載年月日（W3CDTF）: 2014-04-04
• ISSN（掲載誌）: 01676806
• 出版事項（掲載誌）: Springer Science and Business Media LLC
• 対象利用者: 一般
• DOI: 10.1007/s10549-014-2923-9
• 作成日（W3CDTF）: 2014-04-03
• 著作権情報: http://creativecommons.org/licenses/by-nc/4.0
• 関連情報（URI）: http://link.springer.com/content/pdf/10.1007/s10549-014-2923-9.pdf; http://link.springer.com/article/10.1007/s10549-014-2923-9/fulltext.html; http://link.springer.com/content/pdf/10.1007/s10549-014-2923-9
• 参照: A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes; https://cir.nii.ac.jp/crid/1360004231201796608; Eribulin for patients with metastatic extramammary Paget disease: Study protocol for a single‐arm phase <scp>II</scp> trial; https://cir.nii.ac.jp/crid/1360584339778724864; Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial; https://cir.nii.ac.jp/crid/1360848656277027968; Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators; https://cir.nii.ac.jp/crid/1360848661749663104
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• 提供元機関・データベース: Crossref; https://www.crossref.org